伊卡里西德II调节了抗HBV活动的线粒体动态
Zhengyun Liu1, Haiyan Yang1, Juan Wen1
1Key Laboratory of Infectious Disease and Biosafety, Provincial Department of Education, Zunyi Medical University, Zunyi, Guizhou, China.
Frontiers in pharmacology
|April 16, 2025
概括
伊卡里赛德II (ICS II) 通过调节线粒体动态和减少氧化应激,显示出强大的抗乙肝病毒 (HBV) 活性. 这种天然化合物为HBV感染治疗提供了有前途的治疗途径.
科学领域:
- 药理学 药理学是指药理学的学科.
- 病毒学 病毒学
- 细胞生物学 细胞生物学
背景情况:
- 乙型肝炎病毒 (HBV) 感染仍然是一个重大的全球健康问题.
- 目前的HBV治疗方法存在局限性,需要探索新的治疗药物.
- 线粒体动力学越来越被认为是病毒病原发生的关键.
研究的目的:
- 为了评估Icariside II (ICS II) 的抗HBV活性.
- 调查ICS II作用的潜在机制,专注于线粒体动力学.
主要方法:
- 进行了体内和体外测试,包括HBV复制小鼠模型和HepG2.2.15细胞.
- 使用ELISA和qPCR量化HBV标志物 (HBsAg,HBeAg,HBV DNA) 的数量.
- 转录组测序,西布洛特,共聚焦成像和ROS试验被用于分析线粒体动态和氧化应激.
主要成果:
- ICS II 在体内和体外都显著抑制了HBV复制.
- ICS II调节了线粒体动力学,诱导了碎片化和增强了运动性,并改变了参与线粒体分裂/融合的关键蛋白质.
- ICS II治疗导致HBV阳性细胞内细胞内活性氧物种 (ROS) 生产减少.
结论:
- ICS II具有显著的抗HBV潜力.
- ICS II的治疗效果与其调节线粒体动态和降低ROS产生的能力有关.
相关概念视频
01:46Electron Transport Chain: Complex I and II
9.6K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
9.6K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
105
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
105